Lantern Pharma to Present Positive Preclinical Data on the Efficacy of LP-184 for Pancreatic Cancer at the AACR Special Conference for Pancreatic Cancer
September 14 2022 - 8:50AM
Business Wire
Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage
biopharmaceutical company using its proprietary RADR® artificial
intelligence ("A.I.") and machine learning (“M.L.”) platform to
transform the cost, pace, and timeline of oncology drug discovery
and development, today announced that it will present positive
preclinical data on the in vivo efficacy of its drug candidate
LP-184 for pancreatic cancer at the American Association for Cancer
Research (AACR) Special Conference for Pancreatic Cancer, Sept
13-16th, 2022, in Boston, MA.
LP-184 is a small molecule drug candidate and next generation
acylfulvene that preferentially damages DNA in cancer cells that
harbor mutations in DNA damage repair (DDR) genes and that
overexpress the enzyme PTGR1. Pancreatic cancer cells are expected
to be sensitive to LP-184 treatment as around 25% of these cancers
harbor both elevated levels of PTGR1 and mutations in DDR
genes.
The AACR poster, which is being presented in collaboration with
Igor Astsaturov, M.D., Ph.D. at The Marvin and Concetta Greenberg
Pancreatic Cancer Institute at Fox Chase Cancer Center, shows that
LP-184 treatment has potent anti-tumor effects in mouse models of
pancreatic cancer that harbor mutations in the DDR genes ATR or
BRCA1. After two rounds of LP-184 treatment, the ATR and BRCA1
pancreatic cancer mouse models had tumor growth inhibitions of 140%
and 112%, respectively. In these mice, LP-184 treatment was
generally well-tolerated and minimal differences were observed in
body weight and blood counts relative to treatment control
groups.
The AACR presentation will show additional data demonstrating
that LP-184 can act synergistically in vitro and in vivo with
several standard of care or FDA approved agents, including
spironolactone and radiation therapy. These results continue to
demonstrate LP-184’s potential as a therapeutic agent for
pancreatic cancer as a monotherapy or in combination with other
approved therapies.
LP-184 has been granted Orphan Drug Designation by the U.S. Food
and Drug Administration for the treatment of pancreatic cancer,
malignant gliomas, and ATRT, and was also granted a Rare Pediatric
Disease Designation for ATRT. These designations and continued
positive preclinical data will help to accelerate LP-184 towards a
targeted IND submission in Q1 2023 and Phase 1 clinical trials
anticipated to commence in Q2 2023.
Details of the poster presentation are listed below and can be
found on the AACR conference website. A full version of the poster
will be available on Lantern’s website on September 19th, 2022.
Title: LP-184, a tumor site activated small molecule
synthetic lethal therapeutic, is synthetically lethal in pancreatic
cancers with DNA damage repair defects Date and Time:
September 14, 2022, 4:00pm ET Poster Number: B033
Presenter: Aditya Kulkarni, Ph.D., Lantern Pharma
About Lantern Pharma
Lantern Pharma (NASDAQ: LTRN) is a clinical-stage
oncology-focused biopharmaceutical company leveraging its
proprietary RADR® A.I. and machine learning platform to discover
biomarker signatures that identify patients most likely to respond
to its pipeline of genomically-targeted therapeutics. Lantern is
currently developing four drug candidates and an ADC program across
nine disclosed tumor targets, including two phase 2 programs. By
targeting drugs to patients whose genomic profile identifies them
as having the highest probability of benefiting from the drug,
Lantern's approach represents the potential to deliver
best-in-class outcomes.
Please find more information at: Website: www.lanternpharma.com
LinkedIn: https://www.linkedin.com/company/lanternpharma/ Twitter:
@lanternpharma
Forward-looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. These forward-looking statements include, among other
things, statements relating to: future events or our future
financial performance; the potential advantages of our RADR®
platform in identifying drug candidates and patient populations
that are likely to respond to a drug candidate; our strategic plans
to advance the development of our drug candidates and antibody drug
conjugate (ADC) development program; estimates regarding the
development timing for our drug candidates and ADC development
program; expectations and estimates regarding clinical trial timing
and patient enrollment; our research and development efforts of our
internal drug discovery programs and the utilization of our RADR®
platform to streamline the drug development process; our intention
to leverage artificial intelligence, machine learning and genomic
data to streamline and transform the pace, risk and cost of
oncology drug discovery and development and to identify patient
populations that would likely respond to a drug candidate;
estimates regarding patient populations, potential markets and
potential market sizes; sales estimates for our drug candidates and
our plans to discover and develop drug candidates and to maximize
their commercial potential by advancing such drug candidates
ourselves or in collaboration with others. Any statements that are
not statements of historical fact (including, without limitation,
statements that use words such as "anticipate," "believe,"
"contemplate," "could," "estimate," "expect," "intend," "seek,"
"may," "might," "plan," "potential," "predict," "project,"
"target," "objective," "aim," "upcoming," "should," "will,"
"would," or the negative of these words or other similar
expressions) should be considered forward-looking statements. There
are a number of important factors that could cause our actual
results to differ materially from those indicated by the
forward-looking statements, such as (i) the impact of the COVID-19
pandemic, (ii) the risk that our research and the research of our
collaborators may not be successful, (iii) the risk that none of
our product candidates has received FDA marketing approval, and we
may not be able to successfully initiate, conduct, or conclude
clinical testing for or obtain marketing approval for our product
candidates, (iv) the risk that no drug product based on our
proprietary RADR® A.I. platform has received FDA marketing approval
or otherwise been incorporated into a commercial product, and (v)
those other factors set forth in the Risk Factors section in our
Annual Report on Form 10-K for the year ended December 31, 2021,
filed with the Securities and Exchange Commission on March 10,
2022. You may access our Annual Report on Form 10-K for the year
ended December 31, 2021 under the investor SEC filings tab of our
website at www.lanternpharma.com or on the SEC's website at
www.sec.gov. Given these risks and uncertainties, we can give no
assurances that our forward-looking statements will prove to be
accurate, or that any other results or events projected or
contemplated by our forward-looking statements will in fact occur,
and we caution investors not to place undue reliance on these
statements. All forward-looking statements in this press release
represent our judgment as of the date hereof, and, except as
otherwise required by law, we disclaim any obligation to update any
forward-looking statements to conform the statement to actual
results or changes in our expectations.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220914005182/en/
Nicole Leber Investor Relations Associate
ir@lanternpharma.com
Lantern Pharma (NASDAQ:LTRN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Lantern Pharma (NASDAQ:LTRN)
Historical Stock Chart
From Jul 2023 to Jul 2024